Close
10/02/2016
New mechanism of anti-tumour action for the new drug developped at the UAB
A team of UAB researchers and collaborators from the Catalan biotech company Ability Pharmaceuticals (UAB Research Park, Barcelona Synchrotron Park partner), have described a new mechanism of anti-tumour action, identified during the study and development of the new drug ABTL0812.

The study, which has been published in the prestigious journal Clinical Cancer Research, was coordinated by Dr José Miguel Lizcano from the UAB Institute of Neurosciences and Department of Biochemistry and Molecular Biology.

Through the newly identified mechanism, ABTL0812 attacks tumour cells without affecting healthy cells, causing their death by autophagy without activating apoptosis (programmed cell death). It is the first anti-tumour drug to act in this way.

ABTL0812 has recently undergone Clinical Phase I trials in patients with advanced cancer, showing efficacy in several patients (long term stabilization) as well as low toxicity and high tolerability. Clinical Phase II trials are due to start soon in patients with endometrial cancer and lung squamous cell carcinoma.

More news

10/06/2015 The Barcelona Synchrotron Park in the SmartReFlex European project 01/06/2015 SENER and ALBA sign a technology transfer agreement 28/05/2015 Synchrotron light applications for the pharmaceutical industry 20/05/2015 Financial Times ranks ESADE 7th worldwide in open executive education programmes 14/05/2015 Joint promotion in Korea of the Barcelona Synchrotron Park and the Parc Científic de Barcelona 07/05/2015 The UAB ranks well
32 33 34 35 36 37 38 39 40 41 42